Social Media Posts Push Alzheimer's Blood Tests Against Guidelines
Over a third of social media posts promote Alzheimer's blood tests for symptom-free people, contradicting clinical guidelines.
A cross-sectional analysis of 188 social media posts revealed that over a third promoted blood tests for Alzheimer’s as useful for asymptomatic people, contradicting current clinical guidelines. Thirty-six percent of posts framed the test as a useful screening tool for people with no symptoms. Medical guidelines state these tests should not be used to screen individuals without symptoms.
More than one-third of the posts appealed to people’s emotions, including fear and hope. The study was published in the Journal of the American Geriatrics Society.
Financial interests amplify problematic messaging
Accounts with financial interests in blood tests were more than three times as likely to claim the tests work for people without symptoms. Thirty-five posts, or 19% of the total, came from accounts with a clear financial interest. The odds ratio for such accounts making claims about asymptomatic utility was 3.38.
Critical context is frequently missing
Fewer than one in five posts mentioning testing acknowledged the need for clinician involvement in ordering or interpreting the test. Among posts promoting symptom-free screening, only 12% mentioned any downsides. The main potential harm associated with testing asymptomatic people is related to false positives and overdiagnosis, which can cause unnecessary anxiety.
Seventy-five percent of posts carried a promotional tone. Thirteen percent directly encouraged viewers to get tested. Only 36% of posts mentioned research in any general way, and just 24% of those pointed to a specific, identifiable study. Most posts citing concrete evidence referenced a single 2024 study on blood biomarkers. Eleven percent mentioned the test was available directly to consumers without a doctor’s referral.
Experts urge clinician awareness and patient dialogue
Researchers recommend clinicians understand how these tests are portrayed online. They should be prepared to talk to patients about current guidelines, the limitations of the blood tests, and the reality of what positive or negative test results would mean. The standards for when blood-based biomarker testing should be performed were most recently updated in 2024 by an Alzheimer’s Association work group. These standards specify testing should only be performed under clinician supervision and not on asymptomatic individuals.
Clinicians should aim to understand with empathy what is worrying the patient and why the online information has appealed to them. It may also be useful to discuss the modifiable risk factors of dementia that can be addressed. Jenna Smith, a postdoctoral research fellow with the University of Sydney, said the chance of developing dementia is concerning but misleading information risks convincing healthy people to seek out a test that could cause more harm than benefit. Clinicians should be prepared to talk to their patients about current guidelines, the limitations of the blood tests and the reality of what positive or negative test results would mean.
